Objective: To evaluate the intervention effect of low-frequency repetitive transcranial magnetic stimulation (rTMS) among children with autism spectrum disorder (ASD), so as to provide the reference for the treatment scheme of ASD children. Methods: From May to September 2021, children with ASD aged 3 to 12 years were recruited from Elim Training and Ability Development Center as the research subjects and randomly assigned to the intervention group and the control group at ratio of a 1∶1 ratio. The control group only received behavioral training intervention. The intervention group received low-frequency rTMS treatment once a day (5 times/week) on the left dorsolateral prefrontal cortex for 1 month, a total of 20 times, as well as behavioral training. The Autism Behavior Scale (ABC), the Clancy Autism Behavior Scale (CABS), and the Social Responsiveness Scale (SRS) were used to evaluate the behavioral characteristics, symptoms, and social functioning of ASD before and after the intervention, respectively. Adverse events occurring during the intervention period in the intervention group were also collected. The generalized estimation equation was used to compare the differences in scores of each scale between the two groups of children before and after intervention, and to evaluate the intervention effect. Results: Sixty children with ASD were included, with 26 in the intervention group (4 dropouts) and 27 in the control group (3 dropouts). There were 20 and 22 male children in the intervention and control groups, respectively, accounting for 76.92% and 81.48%. The median ages were 5.00 (interquartile range, 1.13) years and 4.50 (interquartile range, 2.00) years, respectively. There were no statistically significant differences between the two groups of children in terms of gender, age, preschool special education time, and total raw scores of Autism Diagnostic Observation Schedule Second Edition (all P>0.05). After one month of intervention, the ABC, CABS, and SRS scores of the intervention group decreased by 16.70, 1.50, and 3.75 points compared to before intervention, respectively, while the control group decreased by 1.07, 0.50, and 1.70 points, respectively (all P<0.05). There was an interaction between the groups and time for ABC scores (P<0.05), while there was no interactions between the groups and time for CABS or SRS scores (both P>0.05). No serious adverse events occurred in the intervention group during the intervention period. Conclusions Low-frequency rTMS treatment has an improvement effect on the behavioral characteristics of children with ASD and shows good safety, and its effect is superior to that of behavioral training treatment. However, it has no obvious improvement effect on social functioning.

【Objective】 To detect the anti-SARS-CoV-2 antibody levels in blood donors in Guangzhou, so as to provide laboratory data support for the collection and clinical use of convalescent plasma. 【Methods】 Anti-SARS-CoV-2 antibodies were measured by ELISA in qualified donors. Among them, 326 donors who gave blood in February 2023 were tested for IgG antibodies, 444 donors were tested for neutralizing antibodies. In July 2023, 398 donors were tested for IgG and IgM. 【Results】 399 of 724 blood samples diluted with normal saline (1∶160) were IgG reactive, with a reactive rate of 55.11%. Chi-square test showed that there was a significant difference in the reactive rate of IgG among samples collected at different times (25.46% in February vs 79.40% in July, χ²=210.74, P<0.01, 95%CI: 7.97, 15.98), but there was no significant difference in the reactive rate between different genders and different age groups. IgM was detected in 5 of 398 blood samples, with a reactive rate of 1.26%. The IgG test results of these five blood donors were all reactive, whereas the nucleic acid test results were negative. Neutralizing antibody was detected in 440 of 444 blood samples, with a reactive rate of 99.10%, and 71.59% of the reactive donors had a neutralizing antibody level of 10 μg/mL or more. 【Conclusion】 Blood donors in Guangzhou have a high level of SARS-CoV-2 antibody, which is sufficient to provide convalescent plasma for clinical treatment.